| 摘要 |
<p>Use of compounds of formula (I), in which n is 3 to 8; q is 5 to 11; R1 represents C¿1-6?alkyl or C1-6alkoxy; s is zero, 1 or 2; X represents oxygen or sulphur; and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy, trifluoromethyl, trifluoromethyloxy, or a group Ph-(CH2)m-Y-(CH2)p-where Ph is optionally substituted phenyl, m and p are independently 0 to 4 and Y is a bond, O, S, or CH=CH, provided that m + p is not greater than 4, or Ar is an optionally substituted tricyclic heteroaryl group (a) in which Y?1¿ is Y(CH¿2?)x where x is 0 or 1 and Y is O, S or NR where R is hydrogen or C1-4alkyl, Z is (CH2)r or -CH=CH-, r is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system, and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of conditions where a calcium channel antagonist is indicated. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.</p> |
